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ABSTRACT
Cobalamin deﬁciency is relatively common, but the great majority
of cases in epidemiologic surveys have subclinical cobalamin deﬁ-
ciency (SCCD), not classical clinical deﬁciency. Because SCCD has
no known clinical expression, its diagnosis depends solely on bio-
chemical biomarkers, whose optimal application becomes crucial
yet remains unsettled. This review critically examines the current
diagnostic concepts, tools, and interpretations. Their exploration
beginswithunderstandingthatSCCDdiffersfromclinicaldeﬁciency
not just in degree of deﬁciency but in fundamental pathophysiology,
causes, likelihood and rate of progression, and known health risks
(whose causation by SCCD awaits proof by randomized clinical tri-
als). Conclusions from SCCD data, therefore, often may not apply to
clinical deﬁciency and vice versa. Although many investigators view
cobalamin testing as unreliable, cobalamin, like all diagnostic bio-
markers, performs satisfactorily in clinical deﬁciency but less well
in SCCD. The lack of a diagnostic gold standard limits the ability
to weigh the performance characteristics of metabolic biomarkers
such as methylmalonic acid (MMA) and holotranscobalamin II,
whose speciﬁcities remain incompletely deﬁned outside their relations
to each other. Variable cutoff selections affect diagnostic conclusions
heavily and need to be much better rationalized. The maximization of
reliability and speciﬁcityof diagnosis is far more important todaythan
the identiﬁcation of ever-earlier stages of SCCD. The limitations of all
current biomarkers make the combination of 2 test result abnor-
malities, such as cobalamin and MMA, the most reliable approach
to diagnosing deﬁciency in the research setting; reliance on one
test alone courts frequent misdiagnosis. Much work remains to be
done. Am J Clin Nutr doi: 10.3945/ajcn.111.013441.
INTRODUCTION
The time appears ripe, 2 decades into the era of population
studies of metabolic cobalamin status, such as NHANES, to
critically review the concepts and the performances of the di-
agnostic biomarkers. Such a review must consider the diverse
perspectives of epidemiologic information users, whether
investigators who mine and reanalyze the data or clinicians who
try to adapt relevant ﬁndings to medical care.
The current state of uncertainty about cobalamin deﬁciency
andaboutitsreliablediagnosisespeciallyrequirescriticalthinking.
This uncertainty is most obvious in the clinical arena, but its
ramiﬁcations extend to and must be understood in the public
health arena. Even though the public health focus is almost
entirely subsumed by subclinical cobalamin deﬁciency (SCCD)
and not clinical deﬁciency, understanding the complicated subject
in either arena begins with the clinical perspective.
Clinicians have become uncertain about what to do with the
many asymptomatic patients with mild biochemical abnormalities
who increasingly displace ill patients as the face of cobalamin
deﬁciency in medical practice, as important distinctions between
clinical disease and biochemical changes blur (1). This incom-
pletely understood SCCD raises quandaries: should such patients
be treated, monitored, or perhaps ignored? And, if treated, for how
long, with what doses, and to what endpoints? The use of oral
cobalamin without a precise diagnosis dominates the landscape
and confuses patients and physicians. Moreover, diagnostic abil-
itieshaveatrophied,mostobviouslyinthedisastrouslossofability
to test cobalamin absorption status, which had been crucial to
informed prognosis and management. Deﬁciency that arises from
intrinsic factor (IF)–related malabsorption usually progresses in-
exorably (and was once lethal), whereas nonmalabsorptive or
minimally malabsorptive deﬁciency progresses very slowly or
not at all (2).
In the public health arena, the emphasis on frequencies and
ﬁnding the earliest possible cases made insufﬁcient room for the
important distinctions between the cobalamin deﬁciencies, their
causes, and their outcomes. The proper balance between the pursuit
of ultimate sensitivity of biochemical detection and overdiagnosis
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THE EVOLUTION OF DIAGNOSTIC TESTING OF
COBALAMIN DEFICIENCY
The early history of testing
From 1949 to the late 1980s cobalamin testing consisted al-
most exclusively of serum cobalamin measurement. The chief
goal was to diagnose or rule out the uncommon but very serious
deﬁciencystate caused in 94% ofcases by perniciousanemia (the
irreversible malabsorptive disease deﬁned by loss of gastric IF
secretion) and intestinal diseases that prevent IF uptake (3). The
clinical hallmark of cobalamin deﬁciency was megaloblastic
anemia (.70% of cases) and/or, somewhat less often, neu-
rologic dysfunction (4).
Readers accustomed to current views of cobalamin as an in-
sensitive test may be surprised to learn that sensitivities were in
fact 95–97% in medical encounters (probably because clinical
deﬁciency appears only after its underlying severe malabsorption
hadsufﬁcientlydepletedcobalaminstores).Speciﬁcitywasalways
viewed asthegreater problembecauseunexplained lowcobalamin
concentrations seemed frequent. Not only did folate deﬁciency
regularly depress serum cobalamin, but pregnancy does so even
more often (4). Many other low cobalamin concentrations without
clinical signs or symptoms had no obvious explanations.
The ﬁrst useful functional metabolic tests appeared in the
1960s.Urinemethylmalonicacid(MMA)becamemeasurable(5)
but was relatively insensitive. A highly sensitive tool identiﬁed
cobalamin and folate deﬁciencies by their impairment of de-
oxyuridine suppression of thymidine uptake by cultured marrow
cells (6). Demand for these cumbersome tests was limited.
Metabolic markers and subclinical deﬁciency
Two developments in the mid-1980s changed the scope of
cobalamin deﬁciency and its determination. One was the ﬁrst
documentation of minimal, often “subclinical,” deﬁciency in
a series of studies from my laboratory in patients who lacked
anemia, macrocytosis, or deﬁciency symptoms (7–12). We used
the deoxyuridine suppression test, which has proven to be as
sensitive as MMA and homocysteine testing (13). Equally im-
portant, the deﬁciencies only rarely arose from disruption of IF-
mediated absorption, such as pernicious anemia (8, 10, 14). Our
discovery of SCCD indicated that many unexplained low co-
balamin concentrations described in the earlier clinical literature
were neither spurious nor artifactual.
The second, nearly concurrent, development was the intro-
duction of assays that reliably detect minute elevations of MMA
and homocysteine, the known substrates of cobalamin-mediated
reactions (15–18). These assays facilitated large surveys that
proved that SCCD was much more common than classical
clinical deﬁciency. The criteria and the performance character-
istics of the diagnostic markers that deﬁne SCCD and clinical
deﬁciency are contrasted in Table 1.
SCCD as a public health issue
Because of SCCD’s high frequency, cobalamin deﬁciency
emerged as a potential public health issue. Research focused on
determining the prevalence of biochemical deﬁciency in pop-
ulations, especially the elderly. Cross-sectional studies also ex-
plored whether health risks accompanied the subclinical state.
Serious suspicions have been raised in relation to neurologic and
cognitive risks, but the mixed record is not detailed here. The
most critical gap remains the absence of clinical trials to
determinewhether any of the statistical links reﬂect causation.
In all this activity, investigators have lost sight of important
distinctions between clinical deﬁciency and SCCD (1, 19, 20),
which are not merely sequential stations along a continuum of
depletion. The sharp disparities begin with pathogenesis, which
is clear in clinical deﬁciency but uncertain in most cases of SCCD.
The causes usually dictate whether the deﬁciency is permanent
and progressive (eg, pernicious anemia) or transient and
ephemeral. The belief that SCCD must inevitably progress to
clinical deﬁciency misappropriated the behavior of pernicious
anemia and continues to color misperceptions about SCCD. The
several courses proposed for SCCD (Figure 1) originate from
scattered published observations but the natural histories of SCCD
remain inadequately studied. Long-term longitudinal studies (21)
have been rare.
SCCD usually lacks the severe IF-related malabsorption that
leads inexorably to clinical deﬁciency. Absorption is normal in
most cases, except for a mild and occasionally antibiotic-
responsive malabsorption limited to food-bound cobalamin in
30–50% of cases (8, 10, 11, 14, 19). Claims of higher malab-
sorption rates (22) used dubious diagnostic criteria (ﬁctitiously
named “Carmel’s criteria”) instead of testing absorption (2). The
limited role of malabsorption (14) may help explain the long
latencyand frequentspontaneous metabolicremissions inSCCD.
These differences illustrate why the facts and therapeutic
imperatives of clinical deﬁciency do not apply automatically
to SCCD. Conversely, population surveys generate data rele-
vant mostly to SCCD that may translate poorly to clinical
patients; the frequency of cobalamin-related biochemical ab-
normalities is ’5–15% in the elderly (23–25), whereas the
rate of pernicious anemia is only 1.9% (26). The increasingly
routine reliance on metabolic testing in clinical medicine is an
example of often wasteful translation from epidemiologic
research (1). Macrocytosis, the hallmark and forerunner of the
anemia of clinical cobalamin deﬁciency, is by deﬁnition irrele-
vant to SCCD and frequently nonspeciﬁc (27, 28); but population
surveys often misattribute normocytic anemia to cobalamin de-
ﬁciency (29–31).
Methodologic and interpretive concerns in SCCD
Achievement of the highest sensitivity and earliest detection
of SCCD has captured substantial diagnostic attention. The ad-
vantages are uncertain, and the attempt increases risks of over-
diagnosis because the much-needed diagnostic “gold” standard
has remained elusive. Another concern for epidemiologic re-
search is that relevant cobalamin deﬁciency exists only in very
small subsets within large populations and applying broad
statistical brushstrokes can obscure the critical minorities.
Analyses that identify (and distinguish between) neglected sub-
sets, such as persons who have clinical deﬁciency or malab-
sorption, may mitigate distortion and add valuable depth to the
ﬂat landscape of broad population analyses.
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The preeminence of serum cobalamin as a diagnostic tool has
comeunderchallenge becauseofits reducedsensitivityfor SCCD.
This decrease is not surprising because most biomarkers lose
sensitivity when applied to mild or marginal conditions. The lack
of a gold standard complicates diagnostic evaluations and de-
cisions, especially when diagnosis depends completely on bio-
markers, as it does in SCCD. (Reliance on biomarkers is lower
in the clinical arena, where clinical manifestations provide a di-
agnostic anchor and serum cobalamin often serves only a conﬁr-
matoryfunction.)Becauseallbiomarkerslacksufﬁcientsensitivity
and speciﬁcity to be reliable in SCCD, reliance on any single
diagnostic test is risky in epidemiologic research and public health
surveys. Which tests to use and how many results must be ab-
normal to provide reasonable diagnostic certainty of deﬁciency
depend on many circumstances, and opinions vary.
All the biomarkers and their assays have idiosyncratic re-
quirementsand confounders,butsomeinﬂuencesseem universal.
Renal dysfunction elevates all biomarker concentrations; MMA
and homocysteine correlate with even minor changes in cre-
atinine and other indexes of glomerular ﬁltration (32, 33),
whereas cobalamin and holotranscobalamin II (holo-TC II) seem
to rise signiﬁcantly only with advanced renal dysfunction and by
uncertain mechanisms (32, 34). Genetic inﬂuences on serum
concentrations, transport, and use are becoming increasingly
apparent. However, cutoff selection remains the most important
external inﬂuence on biomarker data and requires careful, agenda-
free science.
SERUM COBALAMIN MEASUREMENT
Methodologic notes
Cobalamin assays require extraction of cobalamin from its
binding proteins in plasma and conversion of the native coba-
lamins to cyanocobalamin, the nonphysiologic form that serves
as the assay standard. Quantitation, initially based on the growth-
promoting function of cobalamin on microbes, was replaced by
radioisotopic competitive binding techniques using IF as the
cobalamin-binding protein. Transcobalamin (TC) I, also called
haptocorrin, whose afﬁnity for nonfunctional corrin analogs pro-
duces spuriously high “cobalamin” values in sera that contain
substantial amounts of such analogs, must not contaminate the
IF (35).
Although a few reference laboratories prefer microbiologic
assays, immunoenzymatic luminescence methods that rely on
competitivebindingbyIFhavenowreplacedisotopicassays.The
newer methods need attention. They involve proprietary secrets,
and their manufacturers do not always observe transparency (36)
or track assay performance closely. A laboratory survey reported
diagnostic misclassiﬁcations (37). Unfortunately, monitoring and
proﬁciency testing are currently suboptimal because they do not
use optimal low-cobalamin control specimens.
TABLE 1
Performance characteristics of the criteria and biomarkers that deﬁne clinical and subclinical cobalamin deﬁciency (SCCD)
1
Criteria Clinical deﬁciency SCCD
Serum cobalamin ,148 pmol/L Sensitivity: 95–97%
Speciﬁcity: not determined formally but
probably ,80%
Sensitivity: 38–39% (55–84% with higher cutoffs)
2
Speciﬁcity: not determined (appears to decline with
higher cutoffs)
2
Positive predictive value: 58–78%
Elevated serum MMA or plasma
total homocysteine
3
Sensitivity: .95% for either metabolite
Speciﬁcity: not determined formally (MMA
appears to be superior to homocysteine)
Sensitivity: not determinable because abnormality of
one or both is required for SCCD diagnosis
Speciﬁcity: not determinable because no gold
standard exists for comparison (MMA appears to
be superior to homocysteine)
Low serum holo-TC II Sensitivity and speciﬁcity: presumably similar to
those of cobalamin
Sensitivity and speciﬁcity: 2–6% higher than those
of cobalamin
Macrocytosis or macrocytic anemia with
megaloblastic changes such as neutrophil
hypersegmentation
4
Present in 70–80% of cases; may be hard to
recognize in mild cases
Speciﬁcity of macrocytosis or macrocytic anemia
without megaloblastic changes is low
5
SCCD, by deﬁnition, cannot display megaloblastic
anemia, which indicates clinical deﬁciency
Normocytic anemia is almost never attributable to
cobalamin deﬁciency
5
Clinical signs of myelopathy, neuropathy,
or cognitive dysfunction
Present less often than anemia, but data are
imprecise (estimate: 50%)
Findings are often stereotypic but are not
speciﬁc for cobalamin deﬁciency
SCCD cannot be accompanied by clinical signs,
which indicate clinical cobalamin deﬁciency
6
1 MMA, methylmalonic acid; holo-TC II, holotranscobalamin II.
2 If cobalamin cutoffs are 200–300 pmol/L, instead of 148 pmol/L, sensitivity increases but speciﬁcity declines considerably.
3 Neither test is necessary in clinical deﬁciency if the clinical signs are typical and serum cobalamin is low. The tests are always necessary in SCCD
because they are key for its diagnosis.
4 Normocytic anemias, whether in clinical deﬁciency or SCCD, should almost never be attributed to cobalamin deﬁciency. The only exception is
microcytosis caused by iron deﬁciency or thalassemia that coexist with macrocytosis in 5–10% of cases of pernicious anemia; the combination of the 2 often
produces a normal mean corpuscular volume.
5 If macrocytosis or macrocytic anemia exists but is not clearly megaloblastic, the likely diagnosis is either atypical clinical cobalamin deﬁciency or
macrocytosis unrelated to cobalamin, such as alcohol abuse (the most common cause of macrocytosis), myelodysplastic syndrome, or copper deﬁciency.
6 Studies have shown mild electrophysiologic changes in SCCD (11). These changes can improve after therapy, but controlled clinical trials will need to
determine their importance. The same applies to statistical associations with cognitive changes. Whether deﬁciency with isolated electrophysiologic abnor-
malities requires reclassiﬁcation as clinical deﬁciency is not clear.
ASSESSMENT OF COBALAMIN STATUS 3S of 11SThe most worrisome immunoenzymatic assay failures have
been occasional systematic overestimates that seem limited to
samples from overtly cobalamin-deﬁcient patients, often with
pernicious anemia, and without commensurate errors in normal
sera (38–40). These errors have involved many manufacturers’
assays at various times; in one report, 3 of 5 commercial assays
failedto givethe expectedlowcobalamin results inone orboth of
2 patients (40). Sometimes the error is demonstrably due to the
kit’s failure to denature the sample’s anti-IF antibody, which
competes with the kit’s anti-IF antibody. An error that affected
73% of cobalamin-deﬁcient specimens was undetected for months
(38). A clinical study attributed an unprecedented 86% rate of
falsely normal cobalamin results to insensitivity of cobalamin
testing (41), but its use of the previously mentioned assay suggests
assay artifact instead (42). The error is hard to detect because it
does not appear toaffect normal sera. Controlsamplesthat contain
anti-IF antibody may be needed. Cobalamin is stable on storage
(43), but spuriously high results can result in blood samples drawn
into certain phlebotomy tubes that contain gel (44).
Performance characteristics
Aside from the mentioned assay artifacts, falsely normal co-
balamin concentrations are infrequent in patients with clinically
expressed deﬁciency. Indeed, the sensitivity of cobalamin con-
centrations ,148 pmol/L (,200 ng/L) usually exceeded 95% in
patients with megaloblastic anemia (15, 17, 18) and was 90% in
a clinical survey that used a .50% decline in MMA concen-
tration after therapy as a gold standard (45). However, sensitivity
fell to 38–39% in nonclinical population surveys that compared
against MMA or homocysteine endpoints (24, 46). These sur-
veys did not determine the speciﬁcity of cobalamin ,148
pmol/L, but positive predictive values were 58–78% in meta-
bolic surveys in which SCCD predominated (23, 24, 46, 47).
One nonclinical population survey, which used highly stringent
MMA criteria (.450 and .750 nmol/L), reported speciﬁcities
of 72% and 75%, respectively, for cobalamin concentrations
,200 pmol/L, along with sensitivities of 55% and 66%, re-
spectively (25).
The sensitivities and speciﬁcities of biomarkers are difﬁcult to
deﬁne in SCCD because the only possible comparators are other
biomarkers, which have their own sensitivity and/or speciﬁcity
limitations. In the examples above, MMAwas elevated more often
than cobalamin,and investigators usually deferred to the abnormal
MMA results. A normal MMA result can serve as evidence
against cobalamin deﬁciency, but distinguishing between a
“falsely normal” cobalamin result and a “falsely abnormal”
MMA result is difﬁcult, especially if abnormalities are mild and
clinical arbiters are lacking. Combined biomarkers (eg, MMA
plushomocysteine)tendedtoperformbetterthaneitheronealone
(23, 24), as did profound degrees of abnormality.
MMA and homocysteine response to therapy can be diag-
nostically helpful, whereas cobalamin and holo-TC II responses
are uninformative because concentrations rise as cobalamin enters
the bloodstream irrespective of antecedent status. However, tests
of biochemical response are not practical in most population
surveys, and “improvement” can also represent regression to the
mean.
Inﬂuence of cutoff selection
Cobalamin studies in the 1950s reported impossibly low
cutoffs, ’,90 pmol/L, perhaps because deﬁnitions were based
in part on very severe deﬁciency (4). Most subsequent studies
have used cutoffs ’,148 pmol/L (,200 ng/L).
When metabolic testing in SCCD uncovered the insensitivity
of serum cobalamin relative to MMA, a marker of incompletely
deﬁned speciﬁcity, some investigators suggested that the cutoff
be moved from ,148 to ,221 or ,258 pmol/L (0.738 pmol/L =
1 ng/L) to capture more abnormalities (23, 47) and emphasized
that 2.9–5.2% of patients with clinical deﬁciency also had co-
balamin concentrations .148 pmol/L (ie, as excellent a 95–97%
sensitivity as that of homocysteine and MMA). The cutoff
changes implied 2 untested premises: that all SCCD requires
treatment and that “early detection” justiﬁes mislabeling many
nondeﬁcient persons. The frequency of falsely low cobalamin
concentrations by metabolic criteria jumped from 22–42% at
cutoffs of ,148 pmol/L (,200 ng/L) to 44–73% at cutoffs of
,201–350 pmol/L (23, 24, 46, 47), as shown in Figure 2.I n
other words, only a minority of the new cases even had SCCD
(and extremely few had clinical deﬁciency). Moreover, MMA
and homocysteine abnormalities continued to be found, even
at high-normal serum cobalamin concentrations (.350 ng/L)
(Figure 2). Despite the issues, many investigators and clinical
laboratories quickly adopted the new cutoffs.
The major impact that such cutoff choices have on the fre-
quency of deﬁciency (23–25, 46–51) is quantiﬁed in Table 2.
Studies that used cutoffs of 248 pmol/L (300 ng/L) labeled 34–
50% of their populations as cobalamin deﬁcient, compared with
FIGURE 1. Schematic illustration of the diverse courses that cobalamin
deﬁciency states may follow, depending on their underlying causes. The
ﬁelds represent, from top to bottom, the normal cobalamin state, subclinical
deﬁciency (mild metabolic abnormalities without clinical signs or symp-
toms), and clinical deﬁciency (mild and then progressively more severe
hematologic and/or neurologic signs and symptoms). The thick arrow (upper
left) marks the onset of gradual cobalamin depletion whose progressions are
arbitrarily represented as linear. Line 1: the depletion produced by severe,
permanent malabsorption typiﬁed by pernicious anemia. Line 2: the less
complete, less inexorable disruption of cobalamin balance (eg, dietary in-
sufﬁciency or a malabsorption limited to food-bound cobalamin). Based on
various published direct or indirect (but nonsystematic) observations, the
diagram posits a slower course of unknown duration that also increases
the time spent transiting through subclinical cobalamin deﬁciency (SCCD),
which may explain why SCCD is more common. At some point, this course
may (a) eventually progress sufﬁciently to produce clinical, symptomatic
deﬁciency, (b) remit completely for reasons that may or may not be known,
(c) accelerate and reach clinical deﬁciency more quickly (eg, chronic gas-
tritis transforms into pernicious anemia as intrinsic factor secretion disap-
pears), or (d) ﬂuctuate indeﬁnitely between normal and mildly subclinical
deﬁciency states. Modiﬁed and expanded from reference 19.
4S of 11S CARMEL5–12% at traditional cutoffs. This impact of cutoff manipulation
calls attention to the difﬁculties that surround the choices.
Other interpretive issues
Spuriously low cobalamin concentrations in pregnancy and
folate deﬁciency limit cobalamin speciﬁcity (4). Variations in
plasma cobalamin-binding proteins can produce low or elevated
cobalamin concentrations because TC I normally carries .80%
of plasma cobalamin and often determines cobalamin concen-
trations (52). TC I deﬁciency may account for as much as 15%
of low cobalamin concentrations (53); if so, it may cause more
low cobalamin concentrations than does pernicious anemia. TC I
deﬁciency often has a genetic origin (54); mutations in both al-
leles cause cobalamin concentrations of ,100 pmol/L, whereas
the more common heterozygous state causes mildly low or bor-
derline cobalamin concentrations (53, 54).
Spuriously high cobalamin concentrations often accompany
elevated TC I levels. The best known causes of dramatic ele-
vations, such as chronic myelogenous leukemia and some can-
cers, are rare (4). Equally high cobalamin concentrations result
from antibodies to TC II (often after hydroxocobalamin injec-
tions) or TC I (55–57), which may account for 8% of high co-
balamin concentrations (58). More widespread are the more
moderate cobalamin and TC I elevations found in renal failure
(34), in blacks compared with other ethnic groups (59), and in
association with homozygosity for a,1,2-fucosyltransferase gene
polymorphisms (60).
SERUM MMA MEASUREMENT
Themetabolicdependenceofisomerizationof L-methylmalonyl
coenzyme A by methylmalonyl coenzyme A mutase with
5#-deoxyadenosylcobalamin as a cofactor, and its independence
from folate metabolism, have made MMA an attractive biomarker
of cobalamin insufﬁciency.
Methodologic notes
Gas chromatographic assay of MMA in urine has been
available since the late 1950s (5) and a more sensitive gas
chromatography/mass spectrometry method appeared in 1979
(61). Sensitive capillary gas chromatography/mass spectrometry
assays with various modiﬁcations soon made it possible to
measure small concentrations in serum accurately and precisely
(15–18). As automation progressed, serum MMA determination
became more widely available.
Performance characteristics
The sensitivity of serum MMA elevation for cobalamin de-
ﬁciency in patients with overt pernicious anemia was usually
.95% (15, 17, 18). Most MMA elevations were large, often in
the thousands of nmol/L (15). In these and similar (62) clinical
settings, MMA, like homocysteine and holo-TC II (62), per-
formed only marginally better than serum cobalamin. All biomarkers
FIGURE 2. The inﬂuence of higher cutoffs for serum cobalamin concen-
trations on the frequency of true deﬁciency in the cases labeled as "deﬁcient"
by each cutoff. True deﬁciency was deﬁned by each study’s abnormal meth-
ylmalonic acid (MMA) and homocysteine results. Results of 4 surveys with
metabolic data that provided the frequencies (or permitted their calculations)
are shown here. This ﬁgure summarizes the cobalamin concentrations and
cutoffs in ng/L ranges in the top line and in pmol/L in smaller font in the
second line (1 ng = 0.738 pmol), which closely approximate the different
points in all 4 studies. The arrowheads that bracket the frequency rates of
metabolically deﬁned deﬁciency in the center box (201–350 ng/L) delineate
the relevant ranges of cobalamin values. The further data breakdowns avail-
able in reference 23 provide more discrete subset rates (italicized in smaller
font).
1Reference 47,
2Reference 23,
3Reference 46,
4Reference 24.
TABLE 2
Inﬂuence of diagnostic cutoff selection on the frequency of “abnormal” serum cobalamin concentrations in epidemiologic surveys of the elderly
1
Source location,
year (reference) Study population n
Compared cobalamin
cutoffs
Frequencies of “abnormal”
cobalamin that resulted
pmol/L %
Denver, 1992 (47) Elderly outpatients 152 ,148 vs ,221 8.5 vs 25.0
Framingham, 1994 (23) Elderly town dwellers 548 ,148 vs ,258 5.3 vs 40.5
Netherlands, 1998 (46) Elderly town dwellers 105 ,150 vs ,260 24.8 vs 60.1
Oklahoma City, 1998 (48) Elderly outpatients 303 ,148 vs ,221 6.3 vs 16.2
United States, 1999 (49) Disabled elderly town-dwelling women 762 ,148 vs ,258 6.2 vs 33.5
Los Angeles, 1999 (24) Elderly town dwellers and outpatients 591 ,140 vs ,258 11.8 vs 50.4
United Kingdom, 2007 (25) Elderly town dwellers in medical registries 2403 ,150 vs ,200 vs ,300 8.6 vs 29.3 vs 71.7
Norway, 2009 (50) Adults aged 47–49 y 3684 ,150 vs ,200 vs ,400 0.4 vs 3.1 vs 64.5
Norway, 2009 (50) Adults aged 71–74 y 3262 ,150 vs ,200 vs ,400 3.1 vs 6.7 vs 67.6
Georgia, 2010 (51) Octogenarians 79 ,148 vs ,185 vs ,258 7.6 vs 11.4 vs 38.0
Georgia, 2010 (51) Centenarians 215 ,148 vs ,185 vs ,258 11.6 vs 22.8 vs 39.1
1 All the surveys focused on elderly subjects, but the Norwegian survey (50) also included middle-aged adults.
ASSESSMENT OF COBALAMIN STATUS 5S of 11Sappear to be less sensitive in SCCD, but no biochemical gold
standard exists against which to compare them reliably. MMA
values are usually only borderline or mildly abnormal in SCCD
and, unlike in clinical deﬁciency, they are rarely .800 nmol/L.
MMA elevation is consistently more frequent than low co-
balamin concentrations in population surveys (23, 24, 30, 50).
Cutoff selections determine the frequency, but this disparity with
cobalamin suggests MMA’s superior sensitivity for cobalamin
deﬁciency (indeed, a normal MMAvalue supports the likelihood
of normal cobalamin status even when cobalamin concentration
is low). Nevertheless, at least some of the isolated MMA ele-
vations reﬂect limitations in MMA speciﬁcity, which has been
difﬁcult to determine reliably. A large Norwegian survey iden-
tiﬁed creatinine, cobalamin, age, and sex as the major identiﬁable
inﬂuences on serum MMA, but these explained only 16% of
MMA variation (50). A smaller study showed that cobalamin
predictedonly2%oftheserumMMAvalue, whereas cystatin C,
an index of glomerular ﬁltration, predicted 8% (33).
Additional inﬂuences on MMA surely exist and require sys-
tematicstudy.Someauthorshavesuggested, but notdocumented,
a role for plasma volume contraction in some unexplained MMA
elevations (15). Antibiotics sometimes lower MMA concen-
trations, which suggests inﬂuences from active propionate me-
tabolism by intestinal bacteria (18, 63). Neither heterozygosity
for genetic methylmalonic aciduria (64) nor MMA-related poly-
morphisms seem, thus far, to elevate serum MMA signiﬁcantly.
The observation of elevated MMA concentrations during the ﬁrst
year of life (65) remains a puzzle. The values return to normal
spontaneously,butstatisticalassociationwithlowercobalaminand
higher homocysteine values (both still normal) and reduction of
MMA concentrations by cobalamin therapy raise the possibility of
mild cobalamin deﬁciency (66).
Given its undetermined speciﬁcity, MMA cannot be the gold
standard for cobalamin deﬁciency (eg, as used in the holo-TC II
literature). Moreover, a follow-up of 432 untreated, asymptomatic
patients with MMA .280 nmol/L showed that MMA ﬂuctuated
over 1–3.9 y (CV: 34%) (21). MMA elevation progressed in only
16% of cases, compared with spontaneous decline in 44% and
no change in the remainder. As these ﬁndings suggest, minor
changes, whether spontaneous or after treatment (41), should not
be overinterpreted (42).
The inﬂuence of cutoff selection
Published MMA cutoffs have ranged from 210 to 480 nmol/L,
sometimes within the same laboratory. Frequencies of MMA
abnormality, and therefore by extension often of SCCD, vary
inversely with the selected cutoff. The Hordaland data (50) aptly
show the effects of cutoff migration (Table 3). As another ex-
ample, the MMA cutoffs in the 4 surveys in Figure 2 (23, 24, 46,
47) ranged from 240 to 370 nmol/L, and their 5–44% frequen-
cies of MMA abnormality diagnoses bore inverse relations to the
cutoffs.
The most commonly applied MMA cutoff is ’270 nmol/L.
Many laboratories deﬁned cutoffs by 3 or 2 SD from the mean
(’.370 or .270 nmol/L, respectively). Others made physio-
logic choices (eg, by demonstration or projection of MMA
concentrations in cobalamin-repleted subjects) as low as 210
nmol/L (67). The maximally suppressed MMA concentration
might represent true normality but it is not necessarily practical
or desirable in clinical or epidemiologic settings. Such MMA
response can help, as it helps when assessing therapeutic ef-
fectiveness (17), but abnormal values can also regress to the
mean. It is also possible that some improvements of mildly el-
evated or even normal MMA merely signify fuller saturation of
the methylmalonyl coenzyme A mutase by its cobalamin cofactor.
On balance, when studies use MMA alone to deﬁne cobalamin
deﬁciency, unusually low MMA cutoffs such as 210 nmol/L (30,
31) compound the risk of overdiagnosis (R Carmel, unpublished
observations, 2010). A potential data-based approach to deﬁning
biomarker cutoffs may be to construct 2-phase regression models
to determine where their slopes change in relation to other bio-
markers (68).
HOLOTRANSCOBALAMIN II
TC I and TC II (those who call TC I haptocorrin refer to TC II
as TC) carry cobalamin in the bloodstream. Holo-TC II, the TC II
fraction with attached cobalamin, forms at the ileal cell and
delivers its cobalamin to tissues so rapidly that ,20–30% of
plasma cobalamin normally exists as holo-TC II at any time.
The remaining cobalamin circulates in holo-TC I, which turns
over slowly with no discernible delivery to cells and is consid-
ered metabolically unavailable.
Two subtly different and, in fact, competing diagnostic claims
about holo-TC II (69) are that low concentrations either indicate
impaired holo-TC II transfer into the bloodstream from the ileal
cell (ie, a marker of cobalamin malabsorption) or denote in-
adequate availability to tissues (ie, metabolic insufﬁciency).Both
claims may be partially true (70), an ambiguity that ultimately
renders the test nonspeciﬁc for either claim. Malabsorption and
deﬁciency can and often do exist without each other (69).
Transient (eg, drug-induced) malabsorption might exist for only
a few weeks or months and produce low holo-TC II concentra-
tions without ever creating cobalamin deﬁciency, which requires
TABLE 3
Inﬂuence of diagnostic cutoff selection on frequency of “abnormal” serum
methylmalonic acid concentrations, as illustrated in middle-aged and
elderly subjects in the Hordaland survey
1
Selected MMA cutoff
Frequency of “abnormal” MMA that
resulted from selected cutoffs
2
3684 adults
aged 47–49 y
3262 adults
aged 71–74 y
%
.210 nmol/L 14.7 36.7
.260 nmol/L 5.3 17.7
.370 nmol/L 1.2 5.2
.750 nmol/L
3 0.1 0.9
1 This survey showed lower rates of cobalamin deﬁciency than most
population surveys to date. Data are from reference 50. MMA, methylma-
lonic acid.
2 The frequencies of “abnormal” results with the use of these cutoffs
may be higher in other populations.
3 This highly stringent cutoff is also likely to select a much higher
proportion of subjects with clinical deﬁciency that arises from malabsorption
(eg, pernicious anemia) and a lower proportion of subjects with subclinical
deﬁciency than do lower cutoffs.
6S of 11S CARMELyearsofstoragedepletion.Tocomplicateholo-TCIIstatusfurther,
the gut may not be the sole contributor to circulating holo-TC
II (69).
Some authors view holo-TC II abnormality as the earliest
possible marker of cobalamin deﬁciency because it occurs in
patients with normal concentrations of all other biomarkers.
Currentresearchcannotproveordisprovesuchconclusions,which
courttautology.Thefullrangeofalternativeinﬂuencesonholo-TC
II concentrations has not been adequately explored.
Methodologic notes
Lindemans et al (71) suggested in 1983 that measurement of
holo-TC II, whose cobalamin is available to cells, may provide
a truer snapshot of cobalamin status than total cobalamin.
Documentation was limited for many years because holo-TC II
concentrations are very small and early methods were crude and
often indirect (69). Reliable study became possible with the
reports of an accurate enzyme-linked immunosorbent assay and
radioimmunoassay in 2002 (72, 73). An automated 2-step sandwich
microparticle enzyme immunoassay centered on an antibody to
holo-TC II (74) replaced the radioimmunoassay in 2008. Ref-
erence intervals are similar but not identical in the 3 methods;
plasma samples might also yield slightly higher values than do
serum samples.
Performance characteristics
Careful clinical assessment has been limited, in part because
cobalamin absorption testing became unavailable after the late
1990s. Reliable studies must resolvewhat holo-TC II reﬂects and
explore potential confounders of results.
Performance assessment has largely relied on statistical com-
parisons in populations that did not include well-characterized
patients. Studies compared sensitivity and speciﬁcity with those of
cobalamin and often used MMA as the benchmark despite its
undeﬁned speciﬁcity. Most receiver operator characteristics–based
comparisons and similar analyses of sensitivity and speciﬁcity
haveshownthatholo-TCIImodestlyoutperformstotalcobalamin,
with areas under the curves of 0.75–0.90 and 0.72–0.85, re-
spectively (25, 62, 75, 76). One study (25) concluded that neither
test is suitable for the screening of asymptomatic populations
(ie, SCCD) because false-positive results outnumber true-positive
ones. A clinical study in 49 patients with early but clinically ex-
pressed deﬁciency concluded that neither metabolic biomarkers
nor holo-TC II outperformed cobalamin as a predictor of response
to cobalamin therapy (62).
The clinical speciﬁcity of holo-TC II, as opposed to its com-
parability against MMA, is unclear. Holo-TC II rises in renal
failure (34), but modest renal insufﬁciency does not affect holo-
TC II or total cobalamin as much as it affects MMA and total
homocysteine concentrations (32). Holo-TC II becomes normal
in patients with pernicious anemia after correction of their co-
balamin deﬁciency but continues to be mildly but signiﬁcantly
lower than in control subjects (70), which supports absorption
status as an independent inﬂuence on holo-TC II values. Whether
prolonged fasting can similarly affect holo-TC II concentrations
isunknown.Afrequentgeneticvariant,thesubstitutionofproline
for arginine in TCN2 codon 259, may impair holo-TC II func-
tion; its effect on serum holo-TC II concentrations is unsettled
(77–79). Suggested but unexplored clinical confounders of holo-
TC II include oral contraceptive use, myelodysplasia and other
hematologic conditions, histiocytic disorders, folate disorders,
and alcoholism (76, 80, 81). A proposed diagnostic advantage
for holo-TC II over cobalamin in pregnancy (82) is inconclusive:
holo-TC II was not measured before pregnancy but its concen-
trations rose postpartum, which suggests that an unrecognized
holo-TC II decline had, in fact, occurred during pregnancy.
The inﬂuence of cutoff choices
Laboratories have used holo-TC IIcutoffsashighas50pmol/L.
A multicenter evaluation of laboratory performance noted cutoffs
between 11 and41pmol/Lin8 studies,andtheauthorsfavored the
higher values as more representative of normality (76). However,
the automated assay that dominates the commercial market iden-
tiﬁed a 95% CI cutoff of 19 pmol/L (74), which was even lower
than the 24 pmol/L cutoff in its predecessor assay (72). The in-
ﬂuence of cutoffs on outcomes awaits formal study. Only one
group has suggested a sex difference invalues, with a lower cutoff
for women aged ,45 y (83).
Other interpretive issues
Miller et al (75) reported that holo-TC II and total cobalamin
results agreed in 93% of cases (Table 4, groups 1 and 4). The
crux to understanding how the 2 biomarkers’ performances dif-
fer lies within the remaining 7%, of whom only 1 in the 2 markers
indicated cobalamin deﬁciency. Clinical, metabolic, and absorp-
tive investigation of this subset would be invaluable.
PLASMA TOTAL HOMOCYSTEINE
Plasma homocysteine has largely comparable sensitivity to
MMA for cobalamin deﬁciency and is also excellent for moni-
toring response to cobalamin therapy (17). However, homo-
cysteine is too limited by its confounders to serve as a cobalamin
status biomarker and I will not discuss it in detail. Its equal
susceptibility to folate changes prevents its use to distinguish
between cobalamin and folate deﬁciencies in epidemiologic
surveys such as the National Health and Nutrition Examination
Survey. Although folic acid fortiﬁcation may have left cobalamin
deﬁciency as the chief inﬂuence on homocysteine concentrations
among the elderly in the United States (84), folate status explains
TABLE 4
Comparison of frequencies of agreement and disagreement between
cobalamin and holo-transcobalamin II (holo-TC II) results in 607 subjects
in the Sacramento Area Latino Study of Aging
1
Group
Cobalamin
results
Holo-TCII
results n
Frequency in
study
population
%
1 Low Low 32 5.3
2 Normal Low 28 4.6
3 Low Normal 14 2.3
4 Normal Normal 533 87.8
1 The cutoff used to differentiate low from normal cobalamin results
was 148 pmol/L. The cutoff used to differentiate low from normal holo-TC
II results was 35 pmol/L. Data are from reference 75.
ASSESSMENT OF COBALAMIN STATUS 7S of 11S15%ofhomocysteinevariation,comparedwith4%forcobalamin
status in European countries without fortiﬁcation (33). Homo-
cysteine is also the most susceptible of the 4 biomarkers to
preanalytic inﬂuences of sample collection and processing, and
it is the only onewith sex-related differences in reference intervals
that require stratiﬁed analyses. A review of expert opinion
provides further discussion of the homocysteine assay and its
interpretations (85).
CONCLUSIONS AND RECOMMENDATIONS
Issues of concepts and goals
Both public health experts and clinicians must consider all the
implications of SCCD’s heavy predominance in population
surveys in contrast to medical encounters. SCCD differs funda-
mentally, not just in degree, from clinical deﬁciency. That SCCD
rarely arises from IF-related malabsorption may explain its un-
likely or delayed progression to clinical deﬁciency. The differ-
ences make unﬁltered equations of ﬁndings and expectations
between the public health and clinical sectors potentially con-
fusingforbothsectors. Epidemiologistshavereportedpotentially
important associationsbetweenSCCDandneurocognitivechanges,
but only prospective clinical trials can transform statistical as-
sociations into causative health risks and prove that intervention
brings beneﬁts. Randomized trials may be unethical in clinical
cobalamindeﬁciency,buttheyareethical,andindeedimperative,in
SCCD.
More comprehensive efforts must be marshalled to satisfy the
US Food and Drug Administration’s charge that researchers
monitor and clarify folic acid fortiﬁcation’s effect on cobalamin
deﬁciency. Despite some intrinsic limitations, only large surveys
can identify enough potential subjects. However, proper focus on
the population subsets at greatest risk may require means to dif-
ferentiatebetweennonmalabsorptiveSCCDandincipientstagesof
pernicious anemia (28); more diverse and sensitive neurologic and
cognitive tests are also needed.
Epidemiologic focus should extend to cobalamin status in
young children (MMA is often high in the ﬁrst year of life),
persons with Helicobacter pylori infection, and chronic users of
drugs that suppress gastric acid secretion. Attention to cobal-
amin excess and its effects may also become necessary. Daily
1000–2000 lg cyanocobalamin self-supplementation has grown,
and this nonphysiologic cobalamin can accumulate substantially
in cells under such circumstances (86). Red cells could become
a valuable research resource.
Methodologic and interpretive issues
The greatest intrinsic source of diagnostic uncertainty in co-
balamin status assessment is the absence of a gold standard for
deﬁciency. This barrier and the limitations of all markers dictate
that researchers no longer rely on any single test. A model for
combining tests in all future research, preferably with the use of
markers of different cobalamin properties and nonoverlapping
confounder inﬂuences, is presented in Table 5. Studies can com-
bine a marker of cobalamin content, such as serum cobalamin or
holo-TC II, with a metabolic function indicator, such as serum
MMA. Despite minor statistical advantages over cobalamin,
holo-TC II awaits systematic study of subjects deﬁned by rele-
vant characteristics that include absorption status, not just
by their MMA status, and of confounding inﬂuences on holo-TC
II results. When considering everything, the best diagnostic
combination currently appears to be cobalamin and MMA. Re-
liable diagnosis of deﬁciency requires abnormal results in both
chosen tests. Basing diagnoses on an abnormality of either test
alone compounds their nonspeciﬁcities and guarantees overdiag-
nosis of deﬁciency. Research must also better assess the speci-
ﬁcity of MMA elevation in SCCD.
The greatest extrinsic source of diagnostic uncertainty (and
noncomparability of studies) for all biomarkers is the highly
variable use of cutoffs. Experts should develop guidelines for
appropriate criteria and methods that laboratories can use when
deﬁning cutoffs.
TABLE 5
Suggested principles for optimal diagnostic testing for cobalamin
deﬁciency in epidemiologic research in the absence of a diagnostic
gold standard
1
Biomarker results
Diagnostic interpretation Cobalamin
2 MMA
Abnormal Abnormal Cobalamin deﬁciency
Normal Abnormal No deﬁciency
3
Abnormal Normal No deﬁciency
4
Normal Normal No deﬁciency
1 Principles and assumptions are as follows: 1) Reliance on one bio-
marker alone, whether the result is normal or abnormal, is inadequate for
reliable biochemical diagnosis when clinical assessment is unavailable or
clinical deﬁciency is absent. 2) The use of all 4 biomarkers, although in-
formative sometimes, is excessive and multiplies the likelihood of diagnostic
categorization disagreements. 3) The choice should include at least one in-
dicator of vitamin amount [total cobalamin or holo-transcobalamin II (holo-
TC II)] and at least one indicator of metabolic function [methylmalonic acid
(MMA) or homocysteine]. 4) Plasma homocysteine, although reasonably
sensitive, has disabling speciﬁcity problems that prevent its selection as
one of the key biomarkers. 5) Although holo-TC II has slightly better sen-
sitivity and speciﬁcity than total cobalamin, the sparse information on alter-
native inﬂuences on holo-TC II (ie, diagnostic confounding and speciﬁcity)
makes cobalamin a superior choice. 6) This schema is less applicable to
clinical cobalamin deﬁciency than to subclinical cobalamin deﬁciency be-
cause clinical ﬁndings can modify some of the interpretations. The diagnos-
tic interpretations shown are consistent with the principle that biochemical
diagnosis of deﬁciency can be certain only when more than one biochemical
abnormality is evident. In some cases, this rule might miss a diagnosis.
2 Serum cobalamin is preferable to holo-TC II because research has
better characterized it and its shortcomings. If holo-TC II testing is sub-
stituted for cobalamin testing in this column, the diagnostic interpretations
in the right-hand column will be similar.
3 The normal cobalamin result in the face of an abnormal MMA result
suggests either metabolic cobalamin deﬁciency with a falsely normal serum
cobalamin concentration or nondeﬁciency with a falsely elevated MMA
concentration. The odds may favor the former formulation but the uncer-
tainty mandates against a diagnosis of deﬁciency in a research study. (In the
clinical setting, other information on the patient can bear on the diagnostic
interpretation; in a research study, the possibility of doing so depends on the
study design.)
4 Falsely low cobalamin: suspect transcobalamin I deﬁciency or folate
deﬁciency if the subject is not pregnant. (If holo-TC II was tested instead
of cobalamin, the diagnostic possibilities include a falsely low holo-TC II,
whose causes remain poorly deﬁned, and cobalamin malabsorption without
cobalamin deﬁciency.)
8S of 11S CARMELThe current cobalamin assay methods also require attention.
The limited transparency of commercial sources and possibly
frequent malfunctions of many immunoenzymatic methods that
disproportionately affect samples from subjects with cobalamin
deﬁciency and can easily escape detection are disquieting. The
inclusion of control samples that contain anti-IF antibody may
improve detection of the error. The microbiological cobalamin
assay may be a viable alternative for large reference laboratories.
Planning for future capabilities
The ability to identify IF-related malabsorption, primarily
pernicious anemia, would greatly improve the categorization of
cobalamin deﬁciency in surveys. Such information is likely to be
as relevant to deﬁciency as the biochemical expression of de-
ﬁciency, and may also hold the key to understanding the putative
neurologic complications when folic acid intake is high (28).
Inclusion of the anti-IF antibody assay, despite its low sensitivity,
seems the best available option after the disappearance of reliable
absorption tests. The antibody test has near-100% speciﬁcity for
pernicious anemia and requires only a serum sample, and lab-
oratories may measure it post hoc in samples with low cobalamin
concentrations. An improved capability for measurement of non-
functional analogs of cobalamin, which can accumulate in some
subjects and may have adverse implications, may also be useful to
future surveys.
The author had responsibility for all parts of the manuscript. He has sub-
mittedapatentapplicationforworkrelatedtotranscobalaminIdeﬁciencyand
its genetic aspects. The author did not declare a conﬂict of interest.
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